Zacks.com featured highlights Yext, Agenus and NCR Voyix
For Immediate Release
Chicago, IL – July 10, 2025 – The stocks in this week’s article are Yext, Inc. YEXT, Agenus Inc. AGEN and NCR Voyix Corp. VYX.
3 Top Earnings Acceleration Stocks to Buy for 2H25
Senior executives and financial analysts focus on steady earnings growth, as this indicates a company’s profitability. However, a rapid rise in earnings can have an even greater effect in driving stock prices higher. Research shows that well-performing stocks often see their earnings accelerate before their stock prices increase.
To that end, Yext, Inc., Agenus Inc. and NCR Voyix Corp. are showing strong earnings growth, making them attractive buys for the second half.
What is Earnings Acceleration?
Earnings acceleration is the incremental growth in a company’s earnings per share (EPS). In other words, if a company’s quarter-over-quarter earnings growth rate increases within a stipulated time frame, it can be called earnings acceleration.
In the case of earnings growth, you pay for something that is already reflected in the stock price. However, earnings acceleration helps spot stocks that haven’t yet caught the attention of investors and, once secured, will invariably lead to a rally in the share price. This is because earnings acceleration considers both the direction and magnitude of growth rates.
An increasing percentage of earnings growth means that the company is fundamentally sound and has been on the right track for a considerable period. Meanwhile, a sideways percentage of earnings growth indicates a period of consolidation or slowdown, while a decelerating percentage of earnings growth may drag prices down.
The above criteria narrowed the universe of around 7,735 stocks to only four. Here are the top three stocks:
Yext
Yext offers a platform that delivers answers to consumer inquiries both in North America and globally. Zacks Rank #2 (Buy) Yext’s expected earnings growth rate for the current year is 37.1%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Agenus
Agenus is a biotechnology company focused on clinical-stage research, working to discover and develop therapies aimed at stimulating the immune system to combat cancer and infections, both in the United States and globally. Agenus currently has a Zacks Rank #2. AGEN’s expected earnings growth rate for the current year is 114.7%.
NCR Voyix
NCR Voyix offers digital commerce solutions designed for retail establishments and dining venues across the United States, the Americas, the Asia Pacific region, Europe, the Middle East, and Africa. NCR Voyix currently has a Zacks Rank #2. VYX’s expected earnings growth rate for the current year is 152.7%.
You can sign up now for your 2-week free trial to the Research Wizard and start using this screen in your trading. Further, you can also create your own strategies and test them first before taking the investment plunge.
The Research Wizard is a great place to begin. It's easy to use. Everything is in plain language. And it's very intuitive. Start your Research Wizard trial today. And the next time you read an economic report, open up the Research Wizard, plug your finds in, and see what gems come out.
Click here to sign up for a free trial to the Research Wizard today.
For the rest of this Screen of the Week article please visit Zacks.com at: https://www.zacks.com/stock/news/2567829/3-top-earnings-acceleration-stocks-to-buy-for-2h25
Follow us on Twitter: https://www.twitter.com/zacksresearch
Join us on Facebook: https://www.facebook.com/ZacksInvestmentResearch Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. Contact: Jim Giaquinto Company: Zacks.com Phone: 312-265-9268 Email: pr@zacks.com Visit: https://www.zacks.com/ Zacks.com provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer. www.zacks.com/disclaimer. Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release. This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research